Biotech News

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds

Aptevo Therapeutics (APVO)Aptevo TherapeuticsCompany update

SEATTLE, WA / ACCESS Newswire / November 11, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter

Related news

Aptevo Therapeutics

Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct. Mipletamig Mipletamig is a...

Recent company news

Stock data

Close
0.41 USD
Market cap
6.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States